Delivery Order SPE2DB24D2106-SPE2DB25FAWKA
- Not listed
- The Defense Logistics Agency awarded a $19,259.62 firm fixed-price delivery order to DMS Pharmaceutical Group Inc. for Cosentyx (secukinumab) 300mg dose-2 pen/ml pharmaceutical products. The delivery order, issued on September 11, 2025, with an ultimate completion date of September 12, 2025, does not utilize a set-aside designation. Performance will be executed in Conshohocken, Pennsylvania. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park...
- The Defense Logistics Agency awarded a delivery order valued at $13,735.58 to DMS Pharmaceutical Group Inc. for Cosentyx (secukinumab) 300mg dose in 2-pen/mL formulation on August 25, 2025. This firm fixed-price delivery order, with an ultimate completion date of August 26, 2025, represents a pharmaceutical supply requirement with performance taking place in Conshohocken, Pennsylvania. The award was made without set-aside designation to DMS Pharmaceutical Group, a woman-owned small business...
- The Defense Logistics Agency awarded a $16.8K delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Cosentyx (secukinumab) 300 mg pen injections. The order, issued on July 25, 2025, with an ultimate completion date of July 28, 2025, represents a firm fixed-price delivery under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with DLA valued at $500 million and valid through November...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order valued at $13,456.01 by the Defense Logistics Agency (DLA) on August 13, 2025. The contract calls for the delivery of Cosentyx Unoready 300 mg pen 2ml pharmaceutical product to a location in Conshohocken, Pennsylvania, with an ultimate completion date of August 14, 2025. This delivery order was issued without a set-aside designation,...
- The Defense Logistics Agency awarded a $8,935.09 firm fixed-price delivery order to DMS Pharmaceutical Group Inc. for Cosentyx (secukinumab) 300mg dose in 2 pen/mL formulation on September 8, 2025, with an ultimate completion date of September 9, 2025. This award carries no set-aside designation and represents performance at the vendor's location in Conshohocken, Pennsylvania. DMS Pharmaceutical Group, a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, is...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract worth $3,382.36 to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The contract is for the supply of COSENTYX UNOREADY 300 MG PEN 2ML, a pharmaceutical product, to support the recurring medical supply needs of military health facilities worldwide. This delivery order is part of a larger $499,999,999 indefinite delivery contract (IDC) held by DMS Pharmaceutical...
- On August 20, 2025, the Defense Logistics Agency awarded a delivery order valued at $10,461.10 to DMS Pharmaceutical Group Inc. for the supply of Cosentyx (secukinumab) 300 mg pen 2 mL injections. This firm fixed-price delivery order, which is expected to be completed by August 21, 2025, represents a discrete purchase under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the DLA. The contract does not utilize a set-aside designation, and the pharmaceutical products will be...
- This federal contract award, valued at $19,934.38, was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract is a firm fixed-price delivery order for the supply of Cosentyx (secukinumab) 300 mg doses. DMS Pharmaceutical Group holds a larger Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, valued at $499,999,999 and valid through November 2026. This IDC allows the DLA to issue...
- The Defense Logistics Agency awarded a firm fixed price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business, to provide Cosentyx 300 mg pens. The potential value of this delivery order is $3,382.36 with a completion date of January 3, 2024. DMS Pharmaceutical Group is an experienced pharmaceutical wholesaler that holds multiple contracts and indefinite delivery vehicles with the Defense Logistics Agency to supply a variety of medical products and prescription...
- The Defense Logistics Agency awarded a delivery order valued at $4,200.08 to DMS Pharmaceutical Group Inc. for Cosentyx (secukinumab) 300 mg pen 2 ml on August 25, 2025, with completion expected by August 26, 2025. This firm fixed-price delivery order represents a specific pharmaceutical requisition issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with DLA under the SPE2DB program, valued at $499.999 billion and extending through November 2026. The award carries no...
- SPE2DB24D2106Indefinite Delivery Contract
- SPE2DB24D2106-SPE2DB25FAWKADelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $29,169.67 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, on September 10, 2025, with an ultimate completion date of September 11, 2025. This firm fixed-price delivery order covers the supply of Cosentyx (secukinumab) 300mg dose in 2-pen packages, with performance to be executed in Conshohocken, Pennsylvania. The contract was awarded without a set-aside designation, allowing the vendor to compete directly in the federal procurement market while leveraging its woman-owned small business status. This delivery order is issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, valued at $499,999,999 and valid through November 2026. As a critical supplier within the federal pharmaceutical supply chain, DMS Pharmaceutical Group has established itself as a primary vendor for the DLA, providing an extensive portfolio of branded and generic prescription drugs, biologics, and medical consumables to military healthcare facilities nationwide. The company's consistent contract awards demonstrate its capability to deliver specialized pharmaceutical products, including complex biologics and specialty medications, directly supporting Department of Defense medical supply requirements globally.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $29.2k | 9/10/25 |